Note: Ingredients listed on restricted chemical lists
EC/CAS
200-334-9/57-50-1
Name of the chemical
Sucrose, pure C12H22O11
Concentration
>=1-<10
General Information
Version
5.3
Revision date
2025-10-15
Product name
Pembrolizumab / Berahyaluronidase alfa Subcutaneous For- mulation
1.2.1 Relevant identified uses
Pharmaceutical
Emergency telephone
+44 (0) 2081548000, +1-908-423-6000
Icons in SDS
Company Information
company name
MSD
e-mail address of the competent person responsible for the Safety Data Sheet
EHSDATASTEWARD@msd.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H360D, H372
Hazard statements
Code
Statements
H360D
May damage the unborn child
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008 Classification of the substance or mixture
Signal word
Danger
Hazard statements
H360D May damage the unborn child. H372 Causes damage to organs through prolonged or repeated exposure.
Prevention
P201 Obtain special instructions before use. P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this prod- uct. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
Response
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
Storage
P405 Store locked up.
Hazardous Ingredients
Pembrolizumab
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumula- tive and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008) as amended by GB-CLP Regulation, UK SI 2019/720, and UK SI 2020/1567) Reproductive toxicity, Category 1B H360D: May damage the unborn child. Specific target organ toxicity - repeated H372: Causes damage to organs through pro- exposure, Category 1 longed or repeated exposure.
